Arthritis Res Ther. 2023;25(1):56 doi 10.1186/s13075-023-03027-5
Evidence from two phase 3 RCTs showed that patients with PsA and axial involvement had greater responses when treated with a once-daily oral dose of 15 mg upadacitinib versus placebo, and a similar or greater response versus adalimumab. Safety results were comparable between patients with or without axial involvement.
There are currently no commonly accepted criteria for identifying axial involvement in PsA, despite identifying and treating patients with PsA and axial involvement remaining an important clinical topic. Given the observed benefits of upadacitinib in treating PsA, and the need for a better understanding of the clinical responses in patients with PsA and axial involvement, this study aimed to assess the efficacy and safety of upadacitinib in treating patients with active PsA and axial involvement.